Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
Complete the form below to unlock access to ALL audio articles.
Open Biosystems, Inc. has announced that the Institute for Molecular Bioscience and Diamantina Institute at the University of Queensland, and the Biotech Research and Innovation Centre (BRIC) along with the University of Copenhagen have recently purchased access to Open Biosystems shRNAmir technologies for RNAi by joining the Open Access RNAi™ Program.
Both institutions purchased access to Open Biosystems' lentiviral shRNAmir human and mouse libraries developed in collaboration with Dr. Greg Hannon and Dr. Steve Elledge and exclusively distributed through Open Biosystems.
"Once complete, the Institute for Molecular Bioscience's lentiviral screening facility will be unique in the Southern Hemisphere," Professor John Hancock, Deputy Director (Research) of the IMB, said.
"Open Biosystems' Open Access RNAi Program will give all of our research groups access to this valuable genomic screening resource. This will allow our researchers to conduct whole genome or customized gene set knock down experiments that will greatly facilitate discovery in our cell, developmental biology and cancer research programs," Prof. Hancock added.
"The lentiviral shRNAmir libraries are important tools for our high throughput genomic facilities," said Professor Kristian Helin, Director of BRIC. "The research groups at University of Copenhagen will now have access to state-of-the art screening facilities to discover novel genes involved in cell-fate decisions and disease."
Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, the RNAi Consortium human and mouse lentiviral shRNA libraries as well as RNAi collections targeting Drosophila, C. elegans and Arabidopsis thaliana. Participation in the Open Access RNAi program, provides researchers the most complete and flexible access to their choice of these rapidly evolving RNAi technologies.